Key result
A 4-week therapeutic lifestyle modification program significantly decreased MCP-1, fasting insulin, and HOMA compared to usual lifestyle in women with metabolic syndrome (all p < .05).
Why the study?
Does a therapeutic lifestyle modification program improve inflammatory chemokines and insulin resistance in women with metabolic syndrome?
RCT (n=29)
Does a therapeutic lifestyle modification program improve inflammatory chemokines and insulin resistance in women with metabolic syndrome?
A short-term therapeutic lifestyle modification program effectively improves inflammatory state and insulin resistance in women with metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Supports short-term lifestyle programs for women with metabolic syndrome; extends RCT evidence on inflammatory and insulin resistance benefits.
BACKGROUND: Although therapeutic lifestyle modification (TLM) effectively improves the values of diagnostic biomarkers of metabolic syndrome, less is known about its effects on inflammatory chemokines and insulin resistance (IR) in patients with this syndrome. Objectives. To examine the effects of a short-term TLM program on inflammatory chemokines (monocyte chemoattractant protein-1 [MCP-1], retinol binding protein-4 [RBP-4]) and IR in subjects with metabolic syndrome. METHOD: Twenty-nine women (aged 66.5 ± 9.5 years) with metabolic syndrome were randomly assigned to the TLM intervention group (n = 16) or control group (n = 13). The TLM intervention group was provided with 4 weeks of health screening, education, exercise, diet, and counseling. Participants in the control group were instructed to maintain their usual lifestyle behavior. Outcome variables measured included MCP-1, RBP-4, fasting glucose, fasting insulin, and homeostasis model assessment (HOMA). An intention-to-treat strategy was not followed, and the final number of subjects in the analysis was 22 (14 in the TLM group and 8 in the control group). RESULTS: After a 4-week TLM program, MCP-1, fasting insulin, and HOMA were significantly decreased in the TLM group compared to those in the control group (all p < .05). CONCLUSIONS: We conclude that a short-term TLM program could be effective for improving inflammatory state and IR, which are significant preceding biomarkers for cardiovascular complications in subjects with metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2010) conducted an RCT in Metabolic syndrome (n=29). Therapeutic lifestyle modification (TLM) program vs. Usual lifestyle behavior was evaluated on MCP-1, RBP-4, fasting glucose, fasting insulin, and HOMA (p=< .05). A 4-week therapeutic lifestyle modification program significantly decreased MCP-1, fasting insulin, and HOMA compared to usual lifestyle in women with metabolic syndrome (all p < .05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: